

# A simple solution for multiple diagnostic challenges

## Profile

**Sector:** Molecular diagnostics (IVD)

**Product type:** Molecular diagnostic kits

**Founded:** 2018

**Team size:** 13

**Technologies:** qPCR & LAMP

## Metrics

### R&D and validation

14 IVD kits (clinical sample preservation, DNA/RNA extraction, detection of +20 targets).

### Diversified product portfolio

3 product lines (end-to-end solutions) addressing multiple markets (IVD, food safety, other markets)

### IVD quality & standards compliance

ISO 9001 - ISO 13485 - GMP

## Team



**Eduardo H. Pagani**  
CEO



**Diego Chouhy**  
CSO & Co-founder



**Germán R. Perez**  
CTO



**Pablo Casal**  
Quality & Supply Chain Manager

## Contact

**Diego Chouhy**

dchouhy@detxml.com.ar

Tel. +54 0341 735-2035

[www.detxml.com.ar](http://www.detxml.com.ar)

## Company


A biotechnology company certified under ISO 9001 and ISO 13485 standards, specializing in the development and production of molecular diagnostic kits for infectious and genetic diseases in humans, as well as for food testing applications.

## Problem and Solution

Dependence on multiple *singleplex* kits results in excessive inventory immobilization, higher operating costs, and product losses due to low turnover and expiration. The *MultiTarget®* format addresses these challenges efficiently.

## Products

DETx MOL provides comprehensive, end-to-end solutions covering the full molecular diagnostics workflow, organized into three main product lines.



## Key differentiator

The company distinguishes itself by delivering versatile, validated, user-friendly products compatible with cost-effective and widely available instrumentation.

## Other information

- ✓ **Advisory and services:** We provide advisory support and B2B development services across multiple molecular application areas.
- ✓ **Commercial expansion:** We are currently undergoing commercial expansion in Argentina, with plans to expand into Latin America during 2026–2027.
- ✓ **Future developments:** The development of molecular point-of-care (PoC) platforms is under evaluation, along with new products for additional application fields (e.g., plant and veterinary diagnostics).

## Key company milestones

